Ann: Trading Halt, page-133

Hi Steini,

Thanks for the info. Looking at the response you received, I'm clearly missing something here, but are you sure that your source is reliable?

The HSV-2 phase II clinical study is already fully funded and without any intention of the Company to secure partnership funding for alleviating any of the cost burden associated with the global roll-out strategy of CardioCel, current cash in bank together with any beefed up sales revenue from CC over the short term certainly ain't gonna cut it.

Who's going to finance the clinical study programs for the additional ADAPT Products under development, who's going to continue funding the scale-up manufacturing and support, and cover all the other upfront high costs associated with the additional sales, marketing, R&D, clinical, and regulatory resources required for the current global roll-out strategy of CC?

But, why exactly when they already hold a controlling ownership interest?

I must be missing something - further thought appreciated